Cardiac Therapeutics in Horses

Area of Science:

• Veterinary Cardiology
• Equine Pharmacology

Background:

• Many cardiac drugs used in horses lack robust evidence and are often based on data from other species.
• There is a growing need to understand the pharmacodynamics and pharmacokinetics of these equine cardiac therapeutics.
• Existing research on antiarrhythmic agents like sotalol, flecainide, and amiodarone provides some insight.

Purpose of the Study:

• To review the current evidence base for cardiac therapeutics in horses.
• To highlight areas where drug efficacy is supported by data versus where it remains speculative.
• To inform clinical decision-making regarding cardiovascular drug use in equine patients.

Main Methods:

• Literature review of existing studies on equine cardiac pharmacology.
• Analysis of data regarding the use of specific drug classes, including antiarrhythmics and ACE inhibitors.
• Evaluation of the evidence supporting or refuting the use of drugs like pimobendan.

Main Results:

• Evidence for the use of ACE inhibitors in managing equine congestive heart failure is encouraging.
• Data on antiarrhythmic agents (sotalol, flecainide, amiodarone) have been recently described.
• The efficacy of certain medications, such as pimobendan, in horses remains speculative and requires further investigation.

Conclusions:

• Clinical application of cardiac drugs in horses should be guided by species-specific evidence.
• Further research is crucial to establish the pharmacodynamics and pharmacokinetics of commonly used equine cardiac medications.
• While some therapies show promise, a significant knowledge gap exists for many cardiovascular drugs in veterinary cardiology.